Q-omics provides the consensus-scored NRG4 profile across patient tissues and cancer cell-line models. NRG4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NRG4 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, NRG4 RNA expression shows 17,144 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where NRG4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NRG4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NRG4 survival associations across molecular data types. NRG4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NRG4 RNA expression–survival associations across cancer types. High NRG4 expression shows unfavorable associations in KIRC, STAD, UVM, LUAD and UCEC, but favorable associations in OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NRG4 RNA expression.
This table summarizes NRG4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NRG4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NRG4 shows lower tumor expression in COAD, KIRC, STAD and KIRP and higher tumor expression in KICH and LUSC. The COAD box plot shows higher NRG4 RNA expression in normal versus tumor tissue (log2 FC = −0.572, t-test p < 0.001).
This table shows molecular features associated with NRG4 in patient tissues and cancer cell lines. In patient samples, NRG4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NRG4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and URINARY_TRACT.
